|
News For MRK;PFE;JNJ;SNY From The Last 14 Days Check below for free stories on MRK;PFE;JNJ;SNY the last two weeks. |
|
|
| May 24, 2013 |
| 07:54 EDT |  | JNJ | Johnson & Johnson drug business should maintain momentum, says Wells Fargo
After attending J&J's bi-annual pharmaceutical business review, Wells Fargo believes that the revenue generated by four of the company's new drugs could double from 2012 to 2015. The firm thinks the company's pharmaceutical unit has one of the best growth outlooks in the sector, and it keeps an Outperform rating on the stock. |
|
| 06:28 EDT | | JNJ | Johnson & Johnson price target raised to $94 from $88 at Leerink
 Subscribe for More Information |
|
| May 23, 2013 |
| 17:04 EDT |  | MRK | Merck's preladenant gave no evidence of efficacy, ends regulatory filing pursuit
Subscribe for More Information |
|
| 10:08 EDT |  | JNJ | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 08:18 EDT | | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
Subscribe for More Information |
|
| 07:31 EDT | | JNJ | Janssen expects to have more than 25 brand line extensions by 2017
Subscribe for More Information |
|
| 06:29 EDT | | JNJ | Johnson & Johnson coverage assumed with an Underperform at Credit Suisse
Subscribe for More Information |
|
| May 22, 2013 |
| 18:52 EDT | | MRK | On The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 13.4% after reporting second quarter earnings that beat expectations and guiding third quarter and full-year earnings above estimates... Pacific Sunwear (PSUN), up 14.3%. ALSO HIGHER: Merck (MRK), up 0.2% after an FDA advisory panel voted 13-3 in support of the safety of initial doses of its insomnia drug suvorexant. DOWN AFTER EARNINGS: DryShips (DRYS), down 4.7%. ALSO LOWER: Apricus Biosciences (APRI), down 11.5% after filing to sell an ungiven amount of stock... NCI Building Systems (NCS) after being replaced by Cynosure (CYNO) in the S&P 600 as of May 31. |
|
| 18:32 EDT | | MRK | Merck's suvorexant for insomnia reviewed by FDA advisory committee
Subscribe for More Information |
|
| 18:06 EDT |  | MRK | Merck insomnia drug gets FDA panel backing, WSJ reports
Merck's insomnia drug suvorexant received a favorable 13-3 vote from an FDA panel on the drug's two proposed starting doses, with the panel splitting the vote on the safety of higher doses, reports the Wall Street Journal. Reference Link |
| |
| 16:16 EDT | | MRK | FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says
Subscribe for More Information |
|
| 16:00 EDT |  | MRK, JNJ | Options Update; May 22, 2013
Subscribe for More Information |
|
| 14:52 EDT | | MRK | FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports
Subscribe for More Information |
|
| 09:39 EDT | | MRK | Active equity option families trading
Subscribe for More Information |
|
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 07:45 EDT |  | MRK | FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 18:56 EDT | | MRK | On The Fly: After Hours Movers
Subscribe for More Information |
| |
|
|
|
|
